<DOC>
	<DOCNO>NCT02577250</DOCNO>
	<brief_summary>The relationship depression trauma well establish . Co-occuring depression post-traumatic stress disorder ( PTSD ) associate severe symptom low level function . Veterans depression PTSD show much high risk suicide individual one disorder . Ketamine show rapid antidepressant effect also therapeutic action PTSD symptom . The purpose study see whether ketamine , give repeat infusion , produce quick sustain improvement depression PTSD symptom individual symptoms effectively treat current treatment .</brief_summary>
	<brief_title>Ketamine Infusions PTSD Treatment-Resistant Depression</brief_title>
	<detailed_description>The propose study pilot study design determine efficacy safety serial ketamine infusion among veteran treatment-resistant depression ( TRD ) well chronic post-traumatic stress disorder ( PTSD ) . The investigator hypothesize six infusion ketamine effective decreasing severity depressive symptom maintain response . Participants male/female veteran ( 18 75 year old ) era military background suffer TRD chronic PTSD . Potential participant recruit Mental Health clinic screen eligibility use two stage process ( phone/chart review , follow interview ) . Participants receive six ketamine infusion Monday-Wednesday-Friday schedule 2 week . On day infusion , participant require stay clinical site 3 hour medication give . Follow-up visit occur different time point course 2 month two week infusion period complete .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Excitatory Amino Acid Antagonists</mesh_term>
	<mesh_term>Central Nervous System Depressants</mesh_term>
	<mesh_term>Excitatory Amino Acids</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Male female veteran age 18 75 year . Participants must telephone home ability hear telephone conversation . Participants must meet current DSMIV criterion major depressive disorder ( MDD ) , single recurrent , without psychotic feature Participants must meet DSM5 criterion current posttraumatic stress disorder ( PTSD ) receive diagnosis PTSD great equal 3 month prior assessment . Current major depressive episode resistant treatment . If applicable , current antidepressant dosage include augment agent and/or frequency duration psychotherapy session must remain stable least 6 week prior begin study . Inability speak English Inability unwillingness provide write informed consent Moderate/severe cognitive impairment . Current lifetime diagnosis psychosisrelated disorder , bipolar I II disorder , substanceinduced mood disorder , mood disorder due general medical condition . Current lifetime diagnosis Cluster B disorder . History moderate severe traumatic brain injury , Parkinson 's disease , dementia type , multiple sclerosis , seizure CNS relate disorder . History comorbid substance disorder within 6 month screen assess use Mini International Neuropsychiatric Interview ( MINI ) , plus positive urine toxicology screen test baseline assessment . Prior use ketamine antidepressant . Clinically unstable medical illness could compromise patient 's ability tolerate likely interfere study procedure ( e.g. , history current myocardial ischemia arrhythmia , congestive heart failure , severe pulmonary , renal , hepatic disease , uncontrolled hypertension ) Current within less 14 day use barbiturate monoamine oxidase inhibitor ( MAOI ) . History antidepressant substanceinduced hypomania . History first degree relative ( ) Axis I psychotic disorder . For woman : pregnancy ( confirm baseline lab test ) , initiation female hormonal treatment within 3 month screen , inability unwillingness use medically accept contraceptive method duration study . Imminent risk suicidal/homicidal ideation and/or behavior intent and/or plan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>ketamine</keyword>
	<keyword>stress disorder , post-traumatic</keyword>
	<keyword>stress disorder , traumatic</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>mental disorder</keyword>
	<keyword>adjuvant , anesthesia</keyword>
	<keyword>analgesic</keyword>
	<keyword>anesthetic</keyword>
	<keyword>anesthetic , dissociative</keyword>
	<keyword>anesthetic , general</keyword>
	<keyword>anesthetic , intravenous</keyword>
	<keyword>excitatory amino acid agent</keyword>
	<keyword>excitatory amino acid antagonist</keyword>
	<keyword>hypnotic sedative</keyword>
	<keyword>molecular mechanism pharmacological action</keyword>
	<keyword>neurotransmitter agent</keyword>
	<keyword>peripheral nervous system agent</keyword>
	<keyword>pharmacologic action</keyword>
	<keyword>physiological effect drug</keyword>
	<keyword>psychotropic drug</keyword>
	<keyword>sensory system agent</keyword>
	<keyword>central nervous system agent</keyword>
	<keyword>central nervous system depressant</keyword>
	<keyword>depression</keyword>
	<keyword>depressive disorder</keyword>
	<keyword>depressive disorder , treatment-resistant</keyword>
	<keyword>behavioral symptom</keyword>
	<keyword>mood disorder</keyword>
	<keyword>therapeutic us</keyword>
</DOC>